Alternatives to guselkumab
1 same-class SPL records vs guselkumab - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Tremfya
About guselkumab
Tremfya is a medicine that can help treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. It works by blocking a protein in your body that causes inflammation.
Used for: Tremfya treats moderate to severe plaque psoriasis in adults and children 6 years and older who weigh at least 88 pounds. It also treats active psoriatic arthritis in adults and children 6 years and older who weigh at least 88 pounds. Tremfya can also treat moderately to severely active ulcerative colitis and Crohn's disease in adults.
1 Anti-IL-23 Monoclonal Antibody peers (wide set)
guselkumab vs risankizumab · FAERS reaction fields
FAERS top-reaction field "Accidental Exposure To Product" shows the widest count spread between guselkumab and risankizumab in this extract (3,138-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | guselkumab | risankizumab |
|---|---|---|
| Accidental Exposure To Product | 3,138 | - |
| Psoriasis | 2,066 | - |
| Needle Issue | 2,054 | - |
| Device Issue | 1,748 | - |
| Device Malfunction | 1,480 | - |
| Product Storage Error | 1,121 | - |
| Device Deployment Issue | 973 | - |
| Inappropriate Schedule Of Product Administration | 897 | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
guselkumab peer mix vs class inventory
Peer mix
0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Anti-IL-23 Monoclonal Antibody: 2 drugs.
Frequently Asked Questions
What same-class SPL records sit beside guselkumab? ▼
Reading a wide Anti-IL-23 Monoclonal Antibody peer set (1 records)
guselkumab (Tremfya) sits in a wide Anti-IL-23 Monoclonal Antibody peer set (1 of 1 class peers shown). Labeled indication field for guselkumab: Tremfya treats moderate to severe plaque psoriasis in adults and children 6 years and older who weigh at least 88 pounds.
Top FAERS reaction fields for guselkumab total 15,107 reports across 10 reactions, set beside risankizumab. Counts are exposure-weighted submissions, not per-patient risk.
Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for guselkumab: see also the generic vs brand label guide when reading Tremfya SPL strings.
Read our methodology - how this data is sourced, computed, and verified.